...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Primary Endpoint Results for Phase 3 BETonMACE Cardio Outcomes Trial were Announced September 30th ****Detailed Trial Data to be Presented at AHA Late Breaking Session Nov 16th & Company Webcast Nov 18th******

Message: $1.25 sure looks dialed in as the low......

It seems like that $1.24/$1.25 price is made of rubber.....each time we hit it we bounce, but as yet we haven't been able to spring much past $1.30......

Dats jes dah way I likes her.....noice and toight.

New Message
Please login to post a reply